Mektovi (binimetinib tablets – Array BioPharma) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has unresectable, advanced, or metastatic melanoma
• Patient meets ONE of the following (i or ii):
• i. Patient meets BOTH of the following (a and b):
• a) Patient has BRAF V600 mutation-positive disease; AND
• b) The medication will be used in combination with Braftovi (encorafenib capsules); OR
• ii. Patient meets BOTH of the following (a and b):
• a) Patient has a NRAS mutation; AND
• b) Patient has tried at least one immune checkpoint inhibitor therapy

Approval duration

1 year